1. Home
  2. STTK vs VUZI Comparison

STTK vs VUZI Comparison

Compare STTK & VUZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.03

Market Cap

275.9M

Sector

Health Care

ML Signal

N/A

Logo Vuzix Corporation

VUZI

Vuzix Corporation

N/A

Current Price

$3.06

Market Cap

246.0M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
VUZI
Founded
2016
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
246.0M
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
STTK
VUZI
Price
$4.03
$3.06
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$6.20
N/A
AVG Volume (30 Days)
375.1K
1.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
27.32
N/A
EPS
N/A
N/A
Revenue
$5,721,000.00
$5,754,556.00
Revenue This Year
N/A
$5.53
Revenue Next Year
N/A
$110.00
P/E Ratio
N/A
N/A
Revenue Growth
245.26
N/A
52 Week Low
$0.69
$1.47
52 Week High
$4.89
$4.29

Technical Indicators

Market Signals
Indicator
STTK
VUZI
Relative Strength Index (RSI) 51.33 57.03
Support Level $3.52 $2.23
Resistance Level $4.23 $3.20
Average True Range (ATR) 0.28 0.19
MACD 0.00 0.08
Stochastic Oscillator 58.62 81.93

Price Performance

Historical Comparison
STTK
VUZI

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About VUZI Vuzix Corporation

Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.

Share on Social Networks: